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Growth hormone (GH) is a key modulator of growth and GH over-secretion can lead to
gigantism. One form is X-linked acrogigantism (X-LAG), in which infants develop GH-
secreting pituitary tumors over-expressing the orphan G-protein coupled receptor, GPR101.
The role of GPR101 in GH secretion remains obscure. We studied GPR101 signaling pathways
and their effects in HEK293 and rat pituitary GH3 cell lines, human tumors and in transgenic
mice with elevated somatotrope Gpr101 expression driven by the rat Ghrhr promoter
(GhrhrGpr101). Here, we report that Gpr101 causes elevated GH/prolactin secretion in trans-
genic GhrhrGpr101 mice but without hyperplasia/tumorigenesis. We show that GPR101 con-
stitutively activates not only Gs, but also Gq/11 and G12/13, which leads to GH secretion but not
proliferation. These signatures of GPR101 signaling, notably PKC activation, are also present
in human pituitary tumors with high GPR101 expression. These results underline a role for
GPR101 in the regulation of somatotrope axis function.
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Normal physical growth is a fundamental biological processthat integrates a multitude of signals from hormonaleffectors, modulators, and target tissues1. While immen-
sely complex, growth is also tightly regulated and highly chor-
eographed to balance energy acquisition and expenditure with the
evolving metabolic needs of the growing body1. Growth hormone
(GH) is the archetypical modulator of growth across many spe-
cies and it has pleiotropic effects on organ metabolism, body
composition and growth, either directly or through factors like
insulin-like growth factor 1 (IGF-1)2.
As a potent hormonal, growth-enhancing pathway, the GH-
IGF-1 axis exists within a canonical network of modulators acting
directly and indirectly on the pituitary cells secreting GH, the
somatotropes. The main regulators from the hypothalamus are
the stimulatory GH releasing hormone (GHRH) and the inhibitor
somatostatin (SST), which act via their receptors at the level of
the somatotrope to regulate GH synthesis and secretion. Per-
ipheral levels of IGF-1 also have an important feedback on GH
secretion from the pituitary, while other hormonal factors like
ghrelin (secreted by the stomach) act to modulate GH secretion in
relation to feeding3.
Pathological dysregulation of GH axis function is rare, due to
its central role in maintaining normal body size, composition and
metabolism. The most severe form of GH-related overactivity is
pituitary gigantism, where somatotrope tumorigenesis leads to
chronic GH hypersecretion during childhood/adolescence4.
Pituitary gigantism can lead to catastrophic overgrowth of long
bones and severe disease effects due to overgrowth of multiple
organ systems4. Nearly half of pituitary gigantism cases are due to
established genetic causes, the most severe form being X-linked
acrogigantism (X-LAG), which is implicated in many of the tallest
humans with pituitary gigantism5–8. X-LAG is characterized by
infant-onset somatotrope tumors and hyperplasia that produce
high levels of GH and prolactin (PRL), due to genomic rearran-
gements on chromosome Xq26.3 leading to duplications invol-
ving the GPR101 gene. GPR101 is highly over-expressed in X-
LAG tumors as compared with normal pituitary7,9.
GPR101 is a G-protein-coupled receptor (GPCR) that is con-
stitutively coupled to Gs and has no known ligand and is therefore
an orphan GPCR10–12. It is expressed at high levels in regions of
the hypothalamus, the nucleus accumbens and in the fetal
pituitary during somatotrope development and maturation12,13.
To better understand the place of GPR101 in somatotrope
development and regulation, we develop herein a transgenic
mouse model (GhrhrGpr101) that expresses the murine ortholog of
the receptor (Gpr101) under the control of the Ghrhr promoter.
This construction drives the expression of the transgene in the
terminally differentiated somatotropes and somatomammotropes
of the POU domain, class 1, transcription factor 1 (POU1F1), also
named Pituitary-specific positive transcription factor 1 (Pit-1),
lineage14,15. This pituitary-specific Gpr101 overexpression in
mice leads to a gigantism phenotype characterized by skeletal
overgrowth accompanied by elevated GH, IGF-1, and PRL
secretion. Chronic GH/IGF-1 hypersecretion in transgenic mice
associates with classical metabolic effects of elevated glucose
levels, decreased fat mass and increased lean mass16. Crucially,
this GH hypersecretion occurs in the absence of pituitary
hyperplasia or tumorigenesis, indicating that the role of Gpr101
in the pituitary enhances secretion rather than enhancing pro-
liferation. In addition, we find that GPR101-induced GH secre-
tion is dependent on Gs and Gq/11 pathways, notably through the
activation of Protein kinase A (PKA) and Protein kinase C (PKC).
We validate these findings in transgenic mice and observe that the
pituitary adenomas of X-LAG patients, that are characterized by
high expression levels of GPR1017, have an increase of PKC
activity compared to other GH-secreting tumors. GPR101 is a
constitutively active GPCR coupled to multiple G proteins that
acts via Gs- and Gq/11-dependent pathways to promote hormonal
activity of the somatotrope axis.
Results
Gpr101 in the pituitary promotes GH secretion in vivo. To
investigate the impact of GPR101 signaling on somatotrope
function, we generated a mouse model (GhrhrGpr101) expressing
Gpr101 under the control of the rat Ghrhr promoter, which
drives expression in terminally differentiated somatotropes and
somatomammototropes of the POU1F1/Pit-1 lineage14,15,17,18.
The rat Ghrhr promoter was fused with FLAG-Gpr101 coding
sequence and the linearized construct (Supplementary Fig. 1a)
was injected into fertilized mouse oocytes. We obtained several
founders that incorporated the transgene (Supplementary
Figs. 1a, b, 3) and showed expression of FLAG-tagged Gpr101 at
the membrane of pituitary somatotropes and somatomammo-
tropes, as assessed by FLAG-staining (Supplementary Fig. 1c) and
colocalization with Ghrhr, Pit-1, GH (Fig. 1a–c), and PRL
(Supplementary Fig. 1k). The mRNA transcripts for the transgene
were also detected in embryos, juvenile, and adult mouse pitui-
taries (Supplementary Fig. 1e, f). We did not find transgene
expression in other brain structures, especially the hypothalamus
(Supplementary Fig. 1g, h). The expression of the protein could
be detected at embryonic day 16 (E16.5) (Supplementary Fig. 1i).
FLAG-Gpr101 did not co-stain with the progenitor marker Sox2,
suggesting it was present only in terminally differentiated cells
(Supplementary Fig. 1j)19. Our transgene was not found to be
expressed in corticotropes, gonadotropes, or thyrotropes (Sup-
plementary Fig. 1l–n).
Our initial step was to characterize the activity of the
somatotrope axis in the GhrhrGpr101 mice versus controls. We
monitored the plasma levels of GH and IGF-1 at different time
points and found that even at the earliest time-point (6 weeks),
the transgenic (Tg) mice had elevated GH and IGF-1 levels
(Fig. 1d, e). As expected, the GH levels decreased with age but
they remained elevated in the Tg lines, in both males and females
(Fig. 1d). IGF-1 remained consistently increased up to the age of
52 weeks (Fig. 1e). We also observed hyperprolactinemia, in both
males and females (Fig. 1f), likely due to the presence of the
transgene in somatomammotropes (Supplementary Fig. 1k). We
followed the growth of male and female mice from 3 to 69 weeks
(Fig. 1g, h). The elevated circulating levels of GH and IGF-1
translated into a significantly increased body length (nose-to-
anus, the tail length being unaffected, Supplementary Fig. 2a) in
the GhrhrGpr101 mice after 24 weeks of age and was more
pronounced after 1 year (Fig. 1g–j). Despite the increased growth
of the GhrhrGpr101 mice, no significant differences occurred
versus wild-type (WT) in terms of body weight (Supplementary
Fig. 2c). However, there were extensive skeletal changes involving
both the axial skeleton and long bones (Fig. 1k). Femoral and
tibial length was increased in the GhrhrGpr101 mice as compared
with controls (Fig. 1l, m and Supplementary Fig. 2e). Other bones
displayed no statistically significant differences between WT and
Tg animals (Supplementary Fig. 2b). Chronic GH/IGF-1
hypersecretion has a series of well-established effects on
metabolism and body composition and these were present in
the GhrhrGpr101 mice. As compared with WT, the GhrhrGpr101
mice of both sexes had significantly lower fat mass (as illustrated
with epididymal white fat, Fig. 2a), while many organ weights
were not significantly altered (Supplementary Fig. 2d). These
effects of lowered fat mass were clearly visualized and quantified
on whole body CT images, as illustrated in Fig. 2b, c. In parallel,
lean mass determined by CT-scan was elevated due to chronic
GH/IGF-1 secretion in the GhrhrGpr101 versus WT (Fig. 2d).
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Fig. 1 Gpr101 promotes GH/IGF-1 and PRL hypersecretion and overgrowth in vivo. a–c Immunofluorescent staining of anterior pituitary from 29-week-
old GhrhrGpr101 Tg mice. Blue: DAPI. Green: FLAG antibody. Red: a Ghrhr antibody, b Pit-1 antibody and c. GH antibody. (×60 magnification, scale bar:
10 µm). These experiments were repeated at least 3 times. d, e Determination in WT (+/+) and GhrhrGpr101 (+/T) (n= 6 mice per group) of plasma levels
of d GH. Males 6W: p= 0.0411, 26W and 52W: p= 0.0022. Females 6, 26, and 52W: p= 0.0022. e IGF-1. Males 6W and 26W: p= 0.0260, 52W:
p= 0.0022. Females 6, 26, and 52W: p= 0.0022. f PRL. Males 6, 26, and 52W: p= 0.0022. Females 6W: p= 0.0043, 26W: p= 0.0087 52W:
p= 0.0022. g, h Growth curves (length, nose-to-anus) of WT (+/+, males n= 4–18 mice, females n= 6–16 mice) and GhrhrGpr101 (+/T, males n= 5–24
mice, females n= 5–13 mice) between week 3 and week 69. i Quantification and statistical analysis of the lengths of mice at different time points. Males
20W: n= 4 (+/+) and 13 (+/T) mice, p= 0.4790; 24W: n= 6 (+/+) and 10 (+/T) mice, p= 0.0493; 53W: n= 15 (+/+) and 24 (+/T) mice,
p= 0.0001. Females 20W: n= 8 (+/+) and 5 (+/T) mice, p= 0.6169; 24W: n= 8 (+/+) and 9 (+/T) mice, p= 0.0349; 53W: n= 8 (+/+) and 13
(+/T) mice, p= 0.0002. j Macroscopic findings regarding body length of WT (+/+) and GhrhrGpr101 (+/T) aged 53 weeks. k CT images of WT (+/+)
and GhrhrGpr101 (+/T) mice (age 27 weeks). Plain arrow indicates skeletal kyphosis and dashed arrow indicates the femur (n= 4–5 mice per group).
l. Extracted femurs of 27-weeks-old WT (+/+) and GhrhrGpr101 (+/T) mice. m Quantification of femur length (n= 12 femurs from 6 mice per group,
p= 0.0001 for Males and Females). All Data are Mean ± S.D. For statistical analysis of all data, a two-sided Mann–Whitney test was used. ns not
significantly different; *p < 0.05; **p < 0.01 ***p < 0.001.
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Furthermore, we noted that the decreased fat mass in the
GhrhrGpr101 mice occurred due to significantly reduced adipocyte
fat content and decreased mean adipocyte area (Fig. 2e, f). Lipid
storage in the GhrhrGpr101 mice was also reduced at the hepatic
level (Fig. 2g). We also noted hepatomegaly in the GhrhrGpr101
male and female mice, which may have occurred as a consequence
of GH/IGF-1 induced organomegaly (Fig. 2h). Chronic GH
hypersecretion in humans is associated with altered carbohydrate
metabolism20. Such effects occurred in GhrhrGpr101 mice of both
sexes, with increased blood glucose concentrations following
intraperitoneal (IP) administration of a glucose load confirming
the diabetogenic action of GH in this model (Fig. 2i)21. The
described phenotypic traits were recapitulated in another Tg
line that incorporated fewer copies of FLAG-Gpr101 the transgene
(Supplementary Fig. 3).
Next, we investigated the pituitary glands of the GhrhrGpr101
mice to assess whether the source of excess GH and PRL secretion
was due to abnormal somatotrope cell proliferation. Remarkably,
gross pathological and microscopic examination of pituitaries
from GhrhrGpr101 showed no evidence of pituitary adenoma
(Fig. 3a, b). There was no evidence of increased proliferation
within the anterior pituitary as assessed by Ki-67 staining and
hyperplasia was not present on reticulin staining (Fig. 3c, e). In
addition, we excluded that the few Ki-67 cells were somatotropes
by co-staining this proliferation marker with GH in immuno-
fluorescence experiments (Fig. 3d). To better understand the
cause of GH hypersecretion, we determined the extent of
hormone presence in the anterior pituitary both at transcriptional
and protein levels, both of which were elevated in the GhrhrGpr101


























































































































































+/+ +/T +/+ +/T
M F
** **
Fig. 2 GH/IGF-1 hypersecretion leads to alterations in GhrhrGpr101 mice body composition. a Picture: Epididymal white fat from WT (+/+) and
GhrhrGpr101 (+/T). Bars: quantification of epididymal white fat weight normalized to total body weight (n= 6 mice/group, p= 0.0022 for males and
females). b Representative CT images segmented for fat of 27-week-old WT (+/+) and GhrhrGpr101 (+/T) mice (n= 6 mice per group). Total volume is in
grayscale and fat volume is in red. Plain white arrows indicate subcutaneous fat and dashed arrows epididymal fat distribution. c Percentage of fat mass in
WT (+/+) and GhrhrGpr101 (+/T) mice (n= 6 mice per group, p= 0.0022) determined by CT-scan analysis. d Percentage of lean mass in WT (+/+) and
GhrhrGpr101 (+/T) mice (n= 6 mice per group, p= 0.0022) determined by CT-scan analysis. e 27-week-old WT (+/+) and GhrhrGpr101 (+/T)
representative histological sections of epididymal adipose tissue stained with H&E. Scale bar: 30 µm. This experiment was repeated at least three times.
f Mean adipocyte area, quantified using at least four fields per whole-slide image, from at least four animals per group (p= 0.0159). g Representative liver
histological sections from 27-week-old WT (+/+) and GhrhrGpr101 (+/T) mice stained with ORO (n= 4 mice per group). Scale bars: 30 µm. h Picture:
extracted livers from WT (+/+) and GhrhrGpr101 (+/T). Bars: quantification of liver weight normalized to body weight (n= 6 mice per group, males:
p= 0.0303, females: p= 0.0130). i GTT of 11 month-old WT (+/+) and GhrhrGpr101 (+/T) mice. GTT was performed after 12 h of fasting. Glucose was
injected IP to starved mice and blood was collected at indicated time points (0, 30, 60, and 90min) to measure blood glucose levels (males: n= 6 mice per
group, females: n= 5 mice per group). 0 min: p= 0.5173 for males and p= 0.7302 for females. 30min: p= 0.0260 for males and p= 0.0317 for females.
60min: p= 0.1970 for males and p= 0.0952 for females. 90min: p= 0.1320 for males and p= 0.4206 for females. All data are presented as Mean ± S.D.
For statistical analysis of all data, a two-sided Mann–Whitney test was used. ns not significantly different; *p < 0.05; **p < 0.01; ***p < 0.001. F Female,
M Male.
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mRNA for GHRH in the hypothalamus as well as Pit-1 and
GHRHR in the pituitary and showed no differences between
GhrhrGpr101 and WT animals (Supplementary Fig. 4a–c). We
confirmed that circulating levels of GHRH or SST were not
significantly altered in GhrhrGpr101 mice (Supplementary
Fig. 4d, e). We then measured the response of somatotropes
from GhrhrGpr101 mice to the major canonical stimulatory signal,
GHRH, in freshly extracted pituitaries using superfusion
chambers. While basal GH levels were slightly elevated as
compared with WT, the peak GH secretion in response to
GHRH was significantly elevated in the GhrhrGpr101 animals
(Fig. 3h). Taken together, the evidence suggests that the chronic
hormonal hypersecretion, skeletal overgrowth and altered body
composition in GhrhrGpr101 mice is most probably due to the
direct action of Gpr101 on somatotropes to promote GH
synthesis and release.
GPR101 is constitutively coupled to Gs, Gq/11, and G12/13. Given
the pronounced enhancement of hormonal secretion due to
increased Gpr101 in the Tg animals, we undertook studies to
clarify the signaling characteristics and pathways that underlie its
actions. Previous work suggested that GPR101 acted through Gs
and increased cyclic adenosine monophosphate (cAMP)
levels7,12,13. We first established a GPR101-transfected model in
Human Embryonic Kidney (HEK)-293 cells and detected a robust
constitutive increase in cAMP levels using a GloSensor cAMP
assay (Fig. 4a)22,23. In order to firmly establish the link between
cAMP production and Gs, we used CRISPR/Cas9 genome editing
to deplete the α subunit of the G-protein families in HEK293 cells
(HEK293.ΔGs, HEK293.ΔGq/11, and HEK293.ΔG12/13)24,25. We
also used a cell line which was depleted of all G protein α subunits
(Gs/olf, Gq/11 and G12/13) except for the Gi/o family (HEK293.
ΔGtot)26. As a consequence, the effect of GPR101 on cAMP in
HEK293.ΔGs and HEK293.ΔGtot was abolished while being
unaffected in cells lacking Gq/11 or G12/13 (Fig. 4a, Supplementary
Fig. 5a). A combined depletion of Gq/11 and G12/13 with a siRNA
approach did not affect the cAMP increase either (Supplementary
Fig. 5b). Consistently, we found that gpr101, the murine ortholog
(70.7% protein sequence identity to the human protein), induced
a similar increase in basal cAMP levels in HEK293 cells (Fig. 4b).
The cAMP levels were of a similar magnitude as those of a control
orphan receptor that is constitutively coupled to Gs, GPR3
(Fig. 4b).
Next, we examined whether GPR101 could be coupled to other G
proteins. To study Gq/11 activation, we measured inositol monopho-
sphate (IP1) accumulation, the stable downstream metabolite of IP3
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Fig. 3 Gpr101 overexpression potentiates GH release but does not lead to hyperplasia/tumorigenesis. a Upper panel: Macroscopic analysis of the
pituitary gland from 27-week-old WT (+/+) and GhrhrGpr101 (+/T) mice. Lower panel: microscopic visualization of pituitary sections after H&E staining.
Scale bar: 150 µm. b High magnification of anterior and posterior pituitaries stained with H&E. Scale bar: 15 µm. c Left panel: Immunohistochemical staining
of the anterior pituitary sections with the cell proliferation marker Ki-67 (scale bar: 15 µm). Blue arrows indicate Ki-67-positive nuclei staining. Right panel:
quantification of the Ki-67 labeling index in pituitary sections of 27-week-old WT (+/+) and GhrhrGpr101 (+/T) mice. The Ki-67 labeling index represents
the percentage of positive nuclei stained by anti-Ki-67 antibody. n= 11 independent areas from staining section of WT (+/+) and GhrhrGpr101 (+/T) (n= 4
mice per group, p= 0.9487). d Immunofluorescent staining of GH (green) and Ki-67 (Red). Scale bar: 10 µm. e Reticulin staining of the anterior and
posterior pituitaries of WT (+/+) and GhrhrGpr101 (+/T) mice (scale bar: 15 µm). f The expression of GH in the pituitary of WT and GhrhrGpr101 mice (aged
27 weeks n= 5, p= 0.0079) was quantified by RT-qPCR. GAPDH was used as a control housekeeping gene. g The content of the GH protein was
quantified by ELISA and normalized to total protein in pituitary lysates of both males and females of the WT (+/+) and GhrhrGpr101 (+/T) genotypes (aged
29 weeks, n= 4, p= 0.0286). h Ex vivo pituitary superfusion analysis. Pituitary glands of WT (+/+) and GhrhrGpr101 (+/T) (aged 29 weeks, n= 3 mice)
were superfused at 0.1 ml min−1 in superfusion chambers. Effluents were collected every 5 min for GH measurement. GHRH (100 nM) was added to the
medium for 15 min and KCl (0.03M) for 20min (as it is indicated with arrows). GH secretion was quantified by ELISA at indicated time points. All the
experiments were independently repeated three times unless stated otherwise. F Female, M Male. For statistical analysis of all data, a two-sided
Mann–Whitney test was used unless stated otherwise. ns not significantly different; *p < 0.05; **p < 0.01; ***p < 0.001.
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Fig. 4 GPR101 is constitutively coupled to Gs, Gq/11, and G12/13. a Measurement of cAMP levels after GPR101 transient transfection in HEK293 WT, ΔGs,
ΔGq/11, ΔG12/13, or ΔGtot. n= 12 independent experiments. b Comparison of constitutive cAMP levels obtained after transient transfection of pGlo.HEK293
with the indicated receptors: ß2AR (n= 6 independent experiments), GPR101 (n= 10 independent experiments), Gpr101 (n= 6 independent experiments),
and GPR3 (n= 6 independent experiments). The values have been normalized to receptor expression to enable direct comparison. GPR101 vs ß2AR:
p= 0.0002; GPR101 vs Gpr101: p= 0.5622. c Measurement of IP1 levels after transient GPR101 transfection in HEK293 WT, ΔGs, ΔGq/11, ΔG12/13, or ΔGtot.
n= 4 independent experiments. d Activated Rho was detected in lysates of HEK293 WT or HEK293ΔGtot transiently transfected with GPR101 following
precipitation with GST-Rho-binding domain (RBD). Shown are representative of at least three independent experiments. See text for details. e Shown are
pictures of immunoblots for the determination of ERK1/2 phosphorylation in WT HEK293 or HEK293 cells deficient for the indicated G proteins and
transiently transfected with GPR101 or empty vector (MOCK). f Immunoblots were quantified by densitometric analysis. The p-ERK1/2 to total ERK1/2 ratio
has been normalized to the MOCK condition. n= 3 independent experiments. g TGF α Shedding assay performed on HEK293 WT, ΔGs, ΔGq/11, ΔG12/13, or
ΔGtot transiently transfected with GPR101. Results are expressed as the percentage of AP activity in the conditioned medium. n= 12 independent
experiments. h TGF α shedding assay in HEK293 ΔGtot transiently transfected with empty vector (MOCK) or GPR101 alone or together with various Gα
proteins and chimeric Gα proteins. Results are expressed as the percentage of AP activity in the conditioned medium. n= 12 independent experiments.
i Co-Immunoprecipitation of FLAG-GPR101 with Anti-FLAG beads followed by immunodetection of HA-tagged Gα proteins with anti-HA antibody on WB
membranes. Full scans of blots from d, e, and i can be found in the Source Data File. All data are Mean ± S.D. AUC area under curve, HSP90 heat shock
protein 90. IB antibody used for blotted membrane, I input, IP immunoprecipitated fraction. Shown are representative pictures of three independent
experiments. R.L.U. Relative Luminescence Unit. For statistical analysis of all data, a two-sided Mann–Whitney test was used. ns not significantly different;
*p < 0.05; **p < 0.01; ***p < 0.001.
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formed as a result of phospholipase Cβ (PLCβ) activation27.
Increasing expression of GPR101 increased IP1 concentrations in
HEK293 cells; this effect was abolished in a Gq/11-null background
but was maintained in the absence of other G proteins (Fig. 4c,
Supplementary Fig. 5c, d). Next, we assessed G12/13 coupling with a
Rho pull-down activation assay and detected the activation of this
pathway in the presence of GPR101 (Fig. 4d). We were unable to
detect Rho activation in the absence of Gα proteins (except Gαi/o),
which pointed to the ability for GPR101 to couple to G12/13
(Fig. 4d).
It is generally accepted that signaling pathways activated by
different G proteins converge on the activation of the mitogen-
activated protein kinase (MAPK) cascade. Thus, we monitored
the phosphorylation of extracellular signal-regulated kinase 1/2
(ERK1/2) in our different HEK293 cell lines. In unmodified cells,
the presence of GPR101 spontaneously increased basal phospho-
ERK1/2 (p-ERK1/2; Fig. 4e, f). The signal was abolished in
HEK293.ΔGtot while we observed that the activation of the
pathway in HEK293.ΔGq/11 or HEK293.ΔG12/13 was unaffected
(Fig. 4e, f). Interestingly, we noticed an increased signal for p-
ERK in HEK293.ΔGs compared to parental cell lines (Fig. 4e, f).
The basal ERK1/2 phosphorylation was increased in HEK293.
ΔGtot (Fig. 4e) but this was likely due to an elevated basal activity
of the remaining Gi/o in those cells as it disappeared following
pertussis toxin (PTX) treatment (Supplementary Fig. 5f). Next,
we used an alkaline phosphatase-transforming growth factor
alpha (AP-TGF α) shedding assay that is able to detect both Gq/11
and G12/13 downstream pathways28,29. Upon transfection of
increasing amounts of GPR101, we observed a higher level of AP-
TGF α activity in the medium as compared to a MOCK-
transfected control (Fig. 4g, Supplementary Fig. 5e). In G-protein-
depleted HEK293 cell lines devoid of either Gα12/13 or Gαq/11
subunits, there was no impact of deletion of these Gα proteins on
AP-TGF α release (Fig. 4g), which supports a combined Gq/11 and
G12/13 coupling for GPR101.
To further analyze the complex coupling profile of GPR101, we
performed a rescue experiment with the shedding assay and
independently transfected each native Gα protein with or without
GPR101 in HEK293.ΔGtot (Fig. 4h). As expected, the transfection
of empty vector (MOCK) or Gαs together with GPR101 gave no
signal over the background (Fig. 4h). The transfection of either
Gαq, Gα11, Gα12, or Gα13 resulted in enhanced shedding of AP-
TGF α into the supernatant (Fig. 4h). The use of a chimeric
promiscuous Gα proteins (Gαqs) confirmed the Gs coupling of the
receptor and the absence of Gi/o family (Gqi1, Gqi3, Gqo, and Gqz)
activation (Fig. 4h). Finally, we confirmed biochemically the
GPR101 coupling profile with a co-immunoprecipitation assay.
We were able to detect the precipitation with GPR101 of Gαs, Gαq,
Gα11, Gα12, and Gα13 but not Gαi1 (Fig. 4i).
GPR101 promotes GH secretion through Gs and Gq/11. In order
to investigate the functional consequences of GPR101-dependent
activation of various G proteins, we studied the rat somato-
mammotrope cell line, GH3, that secretes GH and PRL30. Con-
sistent with the HEK293 data, upon transfection with GPR101 we
observed a significantly elevated basal level of cAMP and IP1
(Fig. 5a, b). Furthermore, we confirmed that the presence of
GPR101 resulted in a time-dependent increase in GH levels in the
cell culture supernatant (Fig. 5c). Next, we identified the path-
ways involved in the GPR101-mediated increase in GH release by
depleting Gαs, Gαq/11, or Gα12/13 in GPR101-transfected GH3 cells
using an siRNA-based approach (Fig. 5d). The ability of siRNAs
to blunt Gs- and Gq/11- mediated GH release was validated by
using GHRHR and the Ghrelin (GHS) receptor (GHSR) as con-
trols, respectively (Fig. 5d)31,32. In GPR101-transfected cells,
depletion of either Gαs or Gαq/11 drastically reduced GH con-
centration, while the knockdown of Gα12/13 had no significant
effect (Fig. 5d).
Next, we sought to better characterize the downstream events
linking GPR101, Gs, Gq/11 and the secretion of GH. In
somatotropes, PKA and PKC are downstream effectors for Gs-
AC-cAMP and Gq/11-PLC β, respectively33. We assessed the effect
of inhibiting PKA and PKC with H89 and Calphostin,
respectively, on GPR101-mediated GH increases34. Both inhibi-
tors strongly impaired GPR101-mediated GH secretion (Fig. 5e).
To determine if this was due to reduced GH synthesis, GH
exocytosis, or both, we measured GH mRNA in our cell cultures
as a surrogate for GH production. The increased GH mRNA seen
in cells transfected with GPR101 was reduced by the PKA
inhibitor H89 but not by the PKC inhibitor Calphostin (Fig. 5f, g).
We confirmed by Western Blot the direct stimulation of PKA
and PKC by GPR101 (Fig. 5h) and we found with siRNA
depletion of Gα subunits that only Gs contributed to PKA
activation while both Gs and Gq/11 played a role in PKC activation
(Fig. 5i, j). The inhibition of both pathways completely blunted
the PKC activation while Gα12/13 depletion had no effect (Fig. 5j).
GPR101 has no effects on proliferation. In the GhrhrGpr101 mice
we had noted a large increase in GH secretion, but no somato-
trope proliferation or tumorigenesis. We therefore studied the
potential links between Gs and Gq/11 pathway activation and
proliferation in GH3 cells. Transfection of increasing amounts of
GPR101 had a negligible impact on proliferation, as compared
with the marked proliferation induced by GHRH stimulation of
GHRHR (Fig. 6a, b). We hypothesized that the cAMP increase
induced by GPR101 might be insufficient to trigger proliferation.
However, although co-transfection of GHRHR (activated by
GHRH) and GPR101 leads to increased cAMP production over
and above that obtained with GHRH-activated GHRHR (Fig. 6c),
this did not translate into increased proliferation (Fig. 6b). In
order to fully exclude a concentration-dependent effect, we
repeated these experiments with a full concentration range of
GHRH in the presence of increasing amounts of GPR101 (Fig. 6d,
e). The potentiation of the cAMP increase was confirmed in GH3
cells, with a leftward displacement of the concentration-response
curve, with no modification of GHRH maximal efficacy (Emax)
(Fig. 6d). Again, the observed increase of GHRH half maximal
effective concentration (EC50) on cAMP increase did not translate
into an increased potency for GHRH-induced proliferation
(Fig. 6e). This likely suggests that the cAMP generated by
GPR101 does not lead to a stimulation of cellular proliferation.
This unexpected divergent effect between the effect of GPR101
and GHRHR signaling on proliferation was further explored in
siRNA studies of G-protein subfamily depletion (with the GHSR
receptor used as a positive control for constitutive Gq/11 and
G12/13 activation) (Fig. 6f). These studies confirmed in our system
the established roles in somatotrope proliferation of GHRHR
(through Gs) and of GHSR (through Gq/11 and G12/13)35,36. For
GPR101, the siRNA directed against Gαs resulted in an unex-
pected increase in proliferation, which echoed the finding of
increased phospho-ERK activity following Gαs depletion descri-
bed above (Fig. 4e, f). This paradoxical increase of proliferation
was also present when Gαs was depleted in the presence of both
GHRHR and GPR101 (Fig. 6f). We reasoned that in GPR101-
transfected GH3 cells, the downstream activation of Gs-AC-
cAMP could mitigate the proliferative effect of the activation of
Gq/11-PLC β PKC. In keeping with the siRNA experiments, in
cells transfected with GPR101, the direct adenylate cyclase acti-
vator forskolin (FSK) and PKA activator 8-Br-cAMP had negative
impacts on proliferation while the PKA inhibitor H89 promoted
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proliferation (Fig. 6g). Thus, in GH3 cells, the activation of Gs by
GPR101 appears to prevent proliferation induced by Gq/11/G12/13,
while promoting GH secretion.
PKC activation in somatotropes is a GPR101 signature in vivo.
Collectively, our results in GH3 cells pointed to PKC as a char-
acteristic feature of GPR101 downstream activation due to the
additive effects of the Gs-AC-cAMP and Gq/11-PLC β- Diacylgly-
cerol (DAG) activation. In Tg GhrhrGpr101 mice, we measured
cAMP and IP1 levels from pituitaries and confirmed that they were
significantly elevated as compared to WT mice (Fig. 7a, b). We then
used an antibody against activated phospho-PKC (at Threonine
638) to demonstrate the presence of significant pools of phospho-
PKC in somatotropes from GhrhrGpr101 animals, whereas phospho-



























































































































































































































































Fig. 5 GPR101 promotes GH secretion through Gs and Gq/11. All the experiments presented here were performed on the GH3 pituitary cell line.
a Determination of cAMP levels (by ELISA) following transient transfection with MOCK or GPR101 plasmid (p= 0.0022). b Determination of IP1 levels (by
ELISA) following transient transfection with MOCK or GPR101 plasmid (p= 0.0006). c Time-dependent (0, 1, 2, and 6H) measurement (by ELISA) of GH
secretion in the cell culture supernatant. The cells were transfected with MOCK (dark grey), GPR101 (green), GHSR (orange), or GHRHR (blue) for 24 h,
then starved for 3 h. For GHSR and GHRHR, cells were stimulated with their respective ligands (GHS or GHRH, 10 nM). GPR101 and MOCK received a
vehicle treatment as control. d GH determination in the cell culture supernatant after 24h-treatment with various siRNAs (Gαs, Gαq/11, or Gα12/13), 24h-
transfection with expression plasmids containing receptors (MOCK, GPR101, GHSR, or GHRHR), 3h-starvation and 6h-stimulation with indicated agonists
(GHS or GHRH, 10 nM). e GH secretion was determined (by ELISA) in the cell culture supernatant following transfection with GPR101 (or MOCK) and
treated with vehicle, H89 (10 µM, p= 0.0286) or Calphostin (10 µM, p= 0.0286). f, g Rat GH mRNA determination by RT-qPCR following transfection
with MOCK or GPR101 (p= 0.0079) (f) and treatment with PKA & PKC inhibitors H89 (10 µM, p= 0.0079) and Calphostin (10 µM, p= 0.6905) (g),
respectively. h Left: Immunoblot for the detection of phosphorylated PKA and PKC in GH3 cells following transfection with MOCK or GPR101. Right:
Quantification by densitometry of immunoblots. Normalization was performed compared to total PKA and PKC proteins in cell lysate. Full scans of blots are
available in the Source Data file. I, j Quantification by densitometry of immunoblots for PKA and PKC in the presence of GPR101 and different siRNAs. The
antiphosphorylated antibody has been normalized to the signal from the antibody against total protein. All data are Mean ± S.D. of n= 8 (b), n= 6 (a, c),
n= 5 (d, f, g, j), n= 4 (e, i), and n= 3 (h) independent experiments. For statistical analysis of all data, a two-sided Mann–Whitney test was used. ns not
significantly different; *p < 0.05; **p < 0.01; ***p < 0.001.
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This led us to consider whether higher PKC activation could be
detected in human pituitaries with high levels of GPR101
expression. Thus, we used pituitary adenomas from X-LAG
patients that are known to overexpress GPR1017. We compared
phospho-PKC signal intensity in Formalin-fixed paraffin-
embedded (FFPE) tissue from pituitary adenomas in X-LAG
patients (n= 3) as compared with a group of acromegaly patients
without GPR101 duplications (n= 9). As shown in Fig. 7d, e,
tumors from X-LAG syndrome cases exhibited markedly elevated
phospho-PKC staining, as compared to the low level seen in
acromegaly controls, including tumors from patients with aryl
hydrocarbon receptor interacting protein (AIP) mutations, an
aggressive, treatment-resistant genetic form of acrogigantism.
These results indicate that this signaling pathway in somatotropes
involving Gs, Gq/11, and G12/13 linked to increased PKC activity in
GhrhrGpr101 and GH3 cells is present in human pituitary tissues
with high GPR101 expression levels.
Discussion
The potential role of GPR101 in somatotropes initially came to
light with the description of X-LAG, in which a duplication on
chromosome Xq26.3 including GPR101 is associated with infant-
onset GH and PRL-secreting pituitary adenomas that express
high levels of GPR1017–9,37. Subsequently, we demonstrated that
GPR101 expression levels appear to mirror the expansion of
somatotrope populations in the maturing human fetal pituitary13.
However, fundamental information on the consequences of
GPR101 signaling in somatotropes has been missing.
Our results in HEK and GH3 cells and in GhrhrGpr101 mice
provide important insights into the role of increased GPR101
expression and activity in pituitary somatotropes. The phenotype
of the GhrhrGpr101 mice was one of chronically elevated GH and
IGF-1 secretion, with the expected effects on growth and body
composition38,39. In addition, hyperprolactinemia was seen,
which indicates that GPR101 facilitates the enhanced secretion of
both GH and PRL. Cell subpopulations that co-secrete various
hormones, such as, somatomammotropes that co-secrete GH and
PRL, could be the source of this hyperprolactinemia. Somato-
mammotropes and other co-secreting pituitary cells are a well-
described phenomenon in normal mice, rats, and humans and in
somatotropinomas, including the rat GH3 cell line40–42. Notably,
the presence of important pools of cells secreting both GH and
PRL has been repeatedly confirmed by single cell transcriptomic
analysis43–45. As in other settings, increased body size and bone
growth (vertebrae and long bones) due to GH/IGF-1 elevation
was accompanied by decreased fat mass and increased lean mass
in the GhrhrGpr101 mice versus wild-type controls (See Fig. 2)46.
These features demonstrate that increased expression of Gpr101
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Fig. 6 GPR101 does not increase GH3 cell proliferation. a Proliferation was measured with XTT cell proliferation kit on GH3 cells transiently transfected
with increasing amounts (0, 25, 50, and 100 ng) of pcDNA3.1 FLAG-GPR101 plasmid (0 ng vs 25 ng p= 0.8182; vs 50 ng p= 0.5887; vs 100 ng
p= 0.6991). b Quantification of proliferation (by using the XTT reagent) of GH3 cells co-transfected with GHRHR and GPR101 (or MOCK) and treated with
vehicle or GHRH at final concentration of 10 nM. c Comparison of cAMP levels (measured by ELISA) in GH3 cells transfected with GHRHR (100 ng) in the
presence of increasing amounts (0, 25, 50, and 100 ng) of GPR101 plasmids, and treated with vehicle (dark grey) or GHRH (10 nM, orange). d, e GH3 cells
transfected with GHRHR (100 ng) and increasing amounts of FLAG-GPR101. The cells were treated with increasing concentration of GHRH. d cAMP levels
measured by ELISA and normalized to vehicle condition. e Proliferation measured with XTT assay. f Effect of the siRNA-mediated depletion of different G
protein α subunits (Gαs, Gαq/11, or Gα12/13) on GH3 proliferation measured Briefly, GH3 cells were incubated with siRNAs (Gαs, Gαq/11, or Gα12/13, at a final
concentration of 1 µM) for 24 h, and then transfected with MOCK, GPR101 (NTS vs Gαs p= 0.0022), GHRHR (NTS vs Gαs p= 0.0022), GPR101+GHRHR
(untreated NTS vs Gαs p= 0.0286, GHRH-treated NTS vs Gαs p= 0.0286) or GHSR (GHS-treated NTS vs Gαq/11 p= 0.0065). GHRHR- and GPR101
+GHRHR-transfected cells were stimulated with GHRH (10 nM) and GHSR-transfected cells with GHS (10 nM). g Determination of the proliferation of
GPR101-transfected GH3 cells treated with vehicle or different pharmacological agents, such as FSK (adenylate cyclase activator, 10 µM), 8-Br-cAMP (PKA
activator, 10 µM), and H89 (PKA inhibitor, 10 µM). All data are Mean ± S.D. of n= 6 independent experiments (except for the co-transfection of GHRHR
with GPR101 in panel f and for experiments of panels d, e where n= 4). For statistical analysis of all data, a two-sided Mann–Whitney test was used. ns not
significantly different; *p < 0.05; **p < 0.01; ***p < 0.001.
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in the mouse pituitary is sufficient to chronically disrupt the GH-
IGF-1 axis and significantly alter body size, composition and
metabolism. Further aspects of Gpr101-related hormonal secre-
tion in mice remain to be explored, such as, the important issue of
potential alterations in GH pulsatility. Similarly, the magnitude of
the secretory responses to GHRH stimulation seen in our ex vivo
experiments of pituitary tissue needs to be balanced against the
greater magnitude of GH responses to GHRH that occur in vivo.
The hyperprolactinemia that is also encountered in the
GhrhrGpr101 mice requires specific studies to determine the pre-
cise mechanisms by which PRL dysregulation occurs and how
this impacts the phenotype of these animals.
It is long-established that both Gq- and Gs-mediated signaling
can drive GH secretion through distinct pathways converging on
[Ca2+]i increases triggering vesicles exocytosis38. Here, we show
that GPR101 can couple constitutively to multiple G-protein
families, namely Gs, Gq/11, and G12/13. This behavior is not
uncommon among GPCRs, especially those from the Rhodopsin
family47 and has been observed for some pituitary receptors. For
example, the GHSR has a similar complex coupling profile (Gq/11,
Gi/o, and G12/13) and high constitutive signaling activity48,49.
Another notable example of such promiscuous coupling is the
pituitary adenylate cyclase-activating polypeptide (PACAP) type I
receptor that possesses some GH secretagogue capacity50–52.
Constitutive activity of GPR101 is a notable feature that most
likely plays a key role in the physiological functions of the
receptor and the pathophysiology of X-LAG syndrome. This is
mirrored by other diseases in endocrinology where the impact of
constitutive activity has already been documented. For example,
the GHSR constitutive activity, when impaired by mutations, is
related to short stature53. Furthermore, activating mutations of
GNAS affecting Gαs lead to McCune-Albright syndrome (post-
zygotic mosaicism) and acromegaly (somatic mutations), while
activating mutations of the thyrotropin-stimulating hormone
(TSH) and luteinizing hormone (LH) receptor are associated with
diseases such as hyperfunctioning thyroid adenoma and familial
male precocious puberty, respectively54,55.
The GhrhrGpr101 mice developed chronic GH/PRL hyperse-
cretion in the absence of adenoma or hyperplasia, indicating that
Gpr101 overexpression can act as a powerful promoter of GH
secretion in mice, even in a non-tumoral setting. In this aspect of
tumorigenesis, the GhrhrGpr101 mice diverge from the phenotype
of X-LAG; this indicates that X-LAG is a multifactorial process
and important factors in its pathogenesis are not addressed by the
current models and remain to be explained. Our results suggest
that increased GPR101 expression in our models intensify Gs and
Gq/11 pathway basal tone due to the constitutive receptor activity.
Furthermore, Gq/11-PLC β-PKC mediated activation appears to
be a prominent pathway by which GPR101 can modulate hor-
monal secretion in the models studied.
Abnormal or constitutive activation of the Gs-cAMP pathway









































































Fig. 7 PKC activation is a signature in somatotropes with high GPR101 expression in vivo. a Quantification of IP1 levels in WT (+/+) and GhrhrGpr101
(+/T) pituitaries by ELISA in mice aged 29 weeks (n= 8 mice per group, p= 0.0005). b Quantification of cAMP levels in WT (+/+) and GhrhrGpr101
(+/T) pituitaries by ELISA in mice aged 29 weeks (n= 4 mice per group, p= 0.0286). c Immunofluorescent staining of Phospho-PKCα (Thr638) (in red)
and DAPI (in blue) in pituitaries from 29-week-old WT (+/+) and WT (+/+) mice (n= 4 mice/group). The results show that the staining for Phospho-
PKCα (Thr638) is increased in tg GhrhrGpr101 mice compared to WT mice. Scale bar: 10 µm. d, e Illustrative examples of immunofluorescent staining of
Phospho-PKCα (Thr638) (in red) and DAPI (in blue) in human GH-secreting pituitary adenomas (d, in total n= 9 patients) that are either AIP WT (upper
panel, n= 6) or AIPmutated (lower panel, n= 3) and illustrative examples of human X-LAG pituitary tumors from two different patients (e, n= 3 patients).
The results show that Phospho-PKC (Thr638) staining in human X-LAG pituitary tumors is elevated. Photos were taken at ×60 magnification. Scale bar:
10 µm. All data are Mean ± S.D. For statistical analysis of all data, a two-sided Mann–Whitney test was used. *p < 0.05; **p < 0.01; ***p < 0.001.
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formation and GH hypersecretion in various forms of acrome-
galy56. As noted above, a strong link between Gs and somatotrope
tumorigenesis due to activating GNAS mutations has been
established in Mc Cune-Albright syndrome and in up to 40% of
sporadic cases of acromegaly57. Moreover, ectopic secretion of
GHRH leads to pituitary hyperplasia and adenomas and it has
been convincingly demonstrated that this was driven directly by
the activation of Gs through the GHRHR in pituitary somato-
tropes58. However, our results suggest that Gs activity in soma-
totropes does not invariably lead to proliferation and, via
GPR101, may even counteract it. Divergent functional effects
between different cAMP-elevating receptors in specialized cells
has been documented for several decades59,60. The results we
obtained may be a manifestation of such compartmentalization of
signaling but will require further investigation to be firmly
demonstrated. Other possible explanations exist for the differ-
ences observed in cellular response to GHRHR or GPR101, like
the pattern of stimulation triggered by the two receptors. Indeed,
when it is expressed, GPR101 activates the Gs continuously, in a
chronic fashion, while GHRHR responds only to an acute sti-
mulation by GHRH.
Collectively, our results demonstrate that GPR101 can drive
GH secretion in the pituitary through a constitutive activation of
both Gs and Gq/11. We propose a model where the effects of
GPR101 in somatotropes result in an elevated GH secretion in
response to physiological stimuli and potentially in somatotrope
axis dysfunction (Fig. 8).
Methods
Reagents. All chemicals used were from Sigma–Aldrich (St. Louis, MO, USA)
unless stated otherwise. Human Ghrelin (trifluoroacetate salt, Cat. No
4033077.0500) and human GHRH (acetate salt, Cat. No 4011472.0001) were
purchased from Bachem (Switzerland). Mouse ghrh was from Phoenix Pharma-
ceuticals (Belmont, CA, USA, Cat. No 031-14). Calphostin C (PKC inhibitor, Cat.
No C6303) and H89 (PKA inhibitor, Cat. No B1427) were purchased from
Sigma–Aldrich. 8-Br-cAMP is from Merck Millipore (Burlington, Massachusetts,
United States, Cat. No 37060590). FSK is from Gentaur (Kampenhout, Belgium,
Cat. No 203-16384-84). The validated siRNAs and Accell Delivery Medium (Cat.
No B-005000-100) were bought from Dharmacon (Horizon Discovery, Cambridge,
UK). Primers used for cloning, RT-PCR and genotyping were from Integrated
DNA Technologies (IDT, Leuven, Belgium).
Plasmids. Human GPR101, β2-adrenoceptor (β2AR) and GPR3 were amplified
from genomic DNA extracted from HEK293 cells. Mouse gpr101 was amplified
from mouse tail genomic DNA. All receptors were cloned into the pIRESpuro
vector (Clontech Laboratories, Mountain View, CA, USA) (for stable transfections)
and/or pcDNA3.1 (Invitrogen Corporation, Carlsbad, CA, USA) (for transient
transfections) after addition of the FLAG epitope (DYKDDDDK) at the N-ter-
minus, preceded by the signal sequence (ss) KTIIALSYIFCLVFA61, unless specified
otherwise. Expression vectors encoding for the human GHRH and the GHS
receptors were purchased from cDNA Resource Center (Bloomsburg, PA, USA,
Cat. No GHRHR00000 and GHSR0A0000, respectively). The pGloSensorTM-22F
cAMP (cAMP GloSensorTM) plasmid was obtained from Promega Corporation
(Madison, WI, USA). Plasmids for AP-TGFα shedding assay (pCAGGS/AP-TGFα)
and the chimeric Gαqs, Gαqi1, Gαqi3, Gαqo, and Gαqz proteins were described else-
where28. The Gαi1, Gαq, Gα11, Gα12, and Gα13 proteins were amplified from the
cDNA of HEK293 cell mRNA. Gαs was amplified from plasmid obtained at cDNA
Resource Center (Bloomsburg, PA, USA). All G proteins were cloned into the
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) after PCR addition of the HA
(YPYDVPDYA) epitope at the N-terminus. The sequence of all plasmid constructs
was validated by sanger sequencing (GIGA genomic platform, Liège, Belgium).
Cell culture and transfection. HEK293 cells (ATCC, Manassas, VA, USA) were
grown in Dulbecco’s Modified Eagle Medium (DMEM, Lonza, Verviers, Belgium)
supplemented with 10% fetal bovine serum (FBS) (International Medical Products,
Cat. No P40-37500, lot P160105), 1% penicillin/streptomycin (Lonza, Verviers, Bel-
gium), and 2mM L-glutamine (Lonza, Verviers, Belgium) at 37 °C and 5% CO2. Stable
pGlo cell lines were selected for 5 weeks with hygromycin B Gold (160 µgml−1,
InvivoGen). Resulting cell clones were checked by FACS analysis. CRISPR/Cas9
generated HEK293 depleted for G proteins have been described elsewhere (ΔGs/olf25,
ΔGq/1162, ΔG12/1363, and ΔGtot26). Forty-eight hour before the experiment, wild-type
(WT) or CRISPR/Cas9 HEK293 cells were transfected with plasmids using calcium
phosphate precipitation method, unless stated otherwise. Rat pituitary tumor GH3
cells (Sigma–Aldrich, Cat. No 87012603) were grown in Ham’s F10 medium (Life
technologies, Cat. No 31550023) supplemented with 15% horse serum (HS,
Sigma–Aldrich, Cat. No H1138), 2.5% FBS, 1% penicillin/streptomycin, and 2mM L-
glutamine and maintained at 37 °C in an atmosphere of 95% air and 5% CO2. Forty-
eight hour before assay, GH3 cells were transfected with plasmids using lipofecta-
mineTM 3000 transfection reagent (Life technologies, Cat. No L3000008), according to
the manufacturer’s recommendations.
GloSensor cAMP assay. We determined cAMP levels with the GloSensor™
technique22 according to the manufacturer’s instructions (Promega, Madison, WI,
USA). For constitutive activity, HEK293 cells stably expressing the GloSensor
Plasmid 22 F were transiently transfected with increasing concentrations (0, 7.5, 15,
and 30 μg) of plasmids containing GPR101 or other receptors (β2AR, Gpr101 and
GPR3). Forty-eight hour later, cells were detached and incubated 1 h in the dark at
room temperature in HBSS assay buffer (120 mM NaCl, 5.4 mM KCl, 0.8 mM
MgSO4, 10 mM HEPES; pH 7.4, 10 mM glucose) containing IBMX (100 µM). Cells
were distributed into 96-well plates (microplate, PS, 96-well, F-bottom, white,
lumitrac, Greiner bio-one, Cat. No 655075). Following injection of the luciferase
substrate, luminescence was directly recorded for 30 min on a Centro XS3 LB 960
reader (Berthold Technologies, Bad Wildbad, Germany). For the experiments on


























































Fig. 8 Proposed model for GPR101-induced GH secretion. [Ca2+]i: Intracellular Calcium; cAMP 3′,5′-cyclic Adenosine Monophosphate, DAG
Diacylglycerol, GH Growth Hormone, IP3 Inositol Triphosphate, PIP2 Phosphatidylinositol 4,5-bisphosphate, PKA Protein Kinase A, PKC Protein Kinase C,
PLCβ Phospholipase Cβ.
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transiently co-transfected with GPR101 (or MOCK) and GloSensor cAMP bio-
sensor and subjected to the same procedure.
Measurement of cAMP levels by ELISA. The Direct cAMP ELISA Kit (Enzo Life
Sciences, Cat. No ADI-900-066) was used for the determination of cAMP levels in
GH3 cells and mouse tissues. GH3 cells were grown in 24-well culture plates and
transfected with increasing concentrations (0, 25, 50, 100, and 150 ng) of plasmid
(MOCK or GPR101). After 48 h, the media was removed, the cells were incubated
in HCl (0.1 M) for 10 min at room temperature and the cell lysate was centrifuged.
For the experiments of co-transfection of GHRHR (50 ng) with increasing con-
centrations (0, 25, 50, 100, and 150 ng) of GPR101, cells were stimulated with
vehicle (PBS) or GHRH (0–300 nM) for 15 min at 37 °C before cell lysate. Pituitary
tissues from 29-week-old GhrhrGpr101 and WT were collected and flash frozen in
liquid nitrogen. Then, they were homogenized in HCl (0.1 M), and centrifuged for
10 min. The supernatant (coming from GH3 or mouse pituitary lysate) was run
directly or stored frozen (−80 °C) for later analysis. The total cAMP was deter-
mined with the ELISA kit following the manufacturer’s instructions.
Quantification of inositol monophosphate. Changes in second messenger ino-
sitol monophosphate were quantified on cell lysates using the IP-One Enzyme-
linked Immunosorbent Assay (ELISA) assay kit (Cisbio, Codolet, France, Cat. No
72IP1PEA/D) according to the manufacturer’s instructions. WT or CRISPR gen-
erated HEK (ΔGs/olf, ΔGq/11, ΔG12/13, and ΔGtot) or GH3 cells were seeded into a
24-well plate (100,000 cells per well) and after overnight incubation, they were
transfected with increasing concentrations (50, 150, and 300 ng) of empty vector
(MOCK) or pcDNA3.1 FLAG-GPR101, by using X-tremeGene 9 DNA transfection
reagent (Roche, Cat. No 39320900). Forty-eight hour post-transfection, cells were
stimulated with vehicle or GHRH (10 nM) when needed, and culture medium was
replaced by 200 μl of provided stimulation buffer and returned to the incubator for
1 h. Cells were then lysed by adding 50 μl of lysis reagent (2.5%) and further
incubated for 30 min at 37 °C. Finally, 50 μl of cell lysate was transferred into the
ELISA plate, and the assay was conducted according to the manufacturer’s
instructions. Pituitary tissues from 29-week-old GhrhrGpr101 and WT mice were
also collected and lysed as the cells and were assayed following the manufacturer’s
instructions.
Measurement of TGFα shedding. WT or CRISPR generated HEK ΔGq/11 or
ΔG12/13 cells were transfected using X-tremeGene 9 DNA transfection reagent
(Roche, Cat. No 39320900) with 36 ng of pCAGGS/AP-TGFα and 14 ng of receptor
(pcDNA3.1 FLAG-GPR101 or pcDNA3.1 FLAG-β2AR) diluted 1/5, 1/2 or not
diluted with pcDNA3.1 empty vector to obtain different amounts of receptor
expression. Twenty-four hour later, 80 µl of conditioned medium was transferred
into a new transparent flat-bottom 96-well plate. When both plates had cooled
down to room temperature, 80 µl of freshly prepared AP solution (1.2 ml Tris-HCl
2M pH 9.5, 0.2 ml NaCl 4M, 0.2 ml MgCl2 1M, 18.4 ml H2O, 200 µl pNPP 1M)
was added into each well. Optical density (OD) at 405 nm was measured directly
and after 1 h of incubation using the WALLAC VICTOR 2 microplate reader
(Perkin Elmer Life Sciences). We calculated relative the percentage of AP activity in
conditioned medium: AP= ΔOD405 CM/(ΔOD405 CM+ ΔOD405 Cell), where
ΔOD405 CM and ΔOD405 Cell denote changes in OD405 in the conditioned medium
(CM) and on the cell surface, respectively, before and after a 1 h incubation in the
presence of pNPP. The relative percentage of AP activity in conditioned medium
was normalized by the relative percentage of AP activity obtained for well trans-
fected with pCAGGS/AP-TGFα and pcDNA3.1 empty vector instead of receptor.
The same experiment was performed in CRISPR generated HEK ΔGtot cells where
GPR101 was co-transfected (by using the X-tremeGene 9 DNA transfection
reagent (Roche, Cat. No 39320900) with empty vector or each of the G proteins
(Gαs, Gαq, Gα11, Gα12, or Gα13) or chimeric G proteins (Gαqs, Gαqi1, Gαqi3, Gαqo, and
Gαqz).
Rho activation assay. WT or ΔGtot HEK293 cells were seeded in 10-cm culture
dishes and transfected with 15 ug of pcDNA3.1 FLAG-GPR101 (or empty vector,
MOCK). After 24 h, cells were starved overnight with FBS-free medium. Cells were
rinsed with ice-cold TBS (25 mM Tris-HCl pH 7.5, 150 mM NaCl), scraped with
cold lysis/binding/wash buffer (0.5 ml) containing protease inhibitors (Roche,
Basel, Switzerland, cOmplete Tablets Mini EDTA-free, EASYpack, Cat. No
04693159001) and incubated on ice for 5 min. Supernatants were obtained by
centrifugation at 16,000 × g for 15 min at 4 °C, and total protein concentration was
determined by the bicinchoninic acid (BCA) assay (Thermo scientific, USA,
PierceTM Protein Assay Kit, Cat. No 23227). Cell lysates (500 µg) were immuno-
precipitated with a GST-tagged Rhotekin Rho-binding domain (RBD) bound to
agarose beads and the abundance of active GTP-bound Rho (A, B, and C) was
analyzed by pull-down assay, by using the Rho activation assay kit (Enzo, Cat No
ADI-EKS-465).
Determination of ERK phosphorylation. WT or CRISPR generated HEK ΔGs/olf,
ΔGq/11, ΔG12/13, and ΔGtot cells were seeded in 35-cm culture dishes and transiently
transfected with empty vector (MOCK) or pcDNA3.1 FLAG-GPR101. Twenty-four
hour later, cells were starved overnight with medium containing 1% FBS. Cells
were immediately put on ice and lysed with cold RIPA Buffer (25 mM Tris–HCl,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; pH 7.6) containing
protease inhibitors (Roche, Basel, Switzerland, cOmplete Tablets Mini EDTA-free,
EASYpack, Cat. No 04693159001) and phosphatase inhibitors (Roche, Basel,
Switzerland, PhosSTOP, EASYpack, Cat. No 04906837001) for 20 min. Lysates
were centrifuged at 15,000 × g for 15 min at 4 °C. Cell lysates (with an equal
amount of protein (20 µg) as detected by bicinchoninic protein assay (BCA,
Thermo scientific, USA, PierceTM Protein Assay Kit, Cat. No 23227) were mixed
with SDS-PAGE reducing sample buffer, boiled at 95 °C, and separated by 10%
SDS-PAGE followed by immunoblotting (transfer to nitrocellulose membrane
(Amersham Protran 0.2 NC 300 mm × 4m, Cat. No 10600001). The membrane
was blocked in Tris-buffered saline containing 0.1% Tween (TBS-T) and 5% fat-
free dry milk powder (Sigma–Aldrich, Skim Milk powder, Cat. No 70166) for
60 min at room temperature. Then, the membrane was incubated in TBS-T con-
taining 5% milk and the primary antibodies overnight at 4 °C. ERK1/2 phosphor-
ylation was detected with an anti-phospho-p44/42 MAPK (ERK1/2) (Y204/Y204,
D13.14.4E) rabbit monoclonal antibody (Cell Signaling Technology, Cat. No
4370 S, 1:2000), anti-p44/42 MAPK (ERK1/2) rabbit monoclonal antibody (Cell
Signaling Technology, Cat. No 4695 S, 1:1000). After washing with TBS-T (3
times), the membrane was incubated in TBS-T containing 5% milk and a secondary
anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody (Cell Signaling
Technology, Cat. No 7074 S, 1:1000 dilution) for 60 min at room temperature. The
membrane was washed in TBS-T, developed for 2 min in a mix (50:50) of Detection
Reagent 1 Peroxide Solution (Thermo scientific, USA, cat. No 1859700) and
Detection Reagent 2 Luminol Enhancer Solution (Thermo scientific, USA, cat. No
1859697). Immunoreactive signal was quantified and signal levels of Phospho-ERK
were normalized to total ERK1/2.
Co-immunoprecipitation of GPR101 receptor with the G proteins. HEK293 cells
were seeded in 10-cm culture dishes and co-transfected with 15 µg of FLAG-
GPR101 (or empty vector, MOCK) and 15 µg of HA-tagged G-protein (Gαs, Gαq,
Gα11, Gα12, Gα13, Gαi1 or empty vector, MOCK) expression vectors. 24 h later, co-
transfected HEK cells were serum starved overnight. Medium was removed and
cells were washed twice in ice-cold PBS and homogenized in 500 µl of cold lysis
buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, 2 mM EDTA, 1%
Triton-X100, 1% protease and phosphatase inhibitor cocktail). The homogenates
were placed on a rotator for 30 min at 4 °C and clarified by centrifugation for
10 min at 10,000 × g and 4 °C. An aliquot of the supernatant was reserved for
analysis of the total cell lysate (Input) and the remaining sample (900 µg) was used
for co-immunoprecipitation with 5 µg of a mouse anti-FLAG antibody (Cell Sig-
naling Technology, Cat. No 8146) for 1 h at 4 °C. After conjugation, Protein A/G
PLUS-Agarose beads (Santa Cruz, Cat. No 2003) were washed and added to the
samples for 1 additional hour on a rotator at 4 °C. Immune complexes were
subsequently washed three times with PBS containing 1% NP-40 and protease and
phosphatase inhibitors, and were resuspended in 100 μl of 1 × SDS buffer and
incubated for 1 h at room temperature. After centrifugation, the supernatant was
removed and directly loaded onto a Tris glycine 4–10% SDS-PAGE gel (100 V, 2 h).
Proteins were then transferred to nitrocellulose membranes (100 V, 90 min) and
probed overnight at 4 °C with a rabbit anti-HA antibody (Cell Signaling Tech-
nology, Cat. No 3724, dilution 1:1000) against the HA-tagged Gα proteins. The
primary antibody was detected using a secondary anti-rabbit IgG horseradish
peroxidase (HRP)-linked antibody (Cell Signaling Technology, Cat. No 7074 S,
1:1000 dilution) for 1 h and the membranes were developed and images were
acquired using the ImageQuant LAS4000 system.
Determination of PKA and PKC phosphorylation. GH3 cells were seeded in 35-
cm culture dishes and transiently transfected with empty vector (MOCK) or
pcDNA3.1.FLAG-GPR101. 24 h later, cells were starved overnight with medium
containing 1% FBS, and then harvested by using ice-cold lysis buffer (20 mM
HEPES, 1% NP-40, 0.1% SDS, 150 mM NaCl, 2 mM EDTA) containing protease
and phosphatase inhibitors for 20 min. Lysates were centrifuged at 15,000 × g for
15 min at 4 °C. The protein concentration was determined by the BCA assay. Cell
lysates (30 µg) were subjected to western blot analysis using conventional SDS-
PAGE (10%) and protein transfer onto nitrocellulose filters. The membrane was
blocked with TBS-T containing 5% Bovine Serum Albumin (BSA, Sigma–Aldrich,
Cat. No A9647) for 60 min at room temperature. Then, the membrane was
incubated in TBS-T containing 5% milk and the primary antibodies overnight at
4 °C. Primary antibodies were used as described in the manufacturer’s protocols:
anti-phospho-PKC-α/ßII (Thr638/641) rabbit monoclonal antibody (Cell Signaling
Technology, Cat. No 9375 S, dilution 1:1000); anti-PKC-α rabbit monoclonal
antibody (Cell Signaling Technology, Cat. No 2056 S, dilution 1:1000); anti-
phospho-PKA(Thr197) mouse monoclonal antibody (Cell Signaling Technology,
Cat. No 4781 S, dilution 1:1000); anti-PKA-α rabbit polyclonal antibody (Cell
Signaling Technology, Cat. No 4782 S, dilution 1:1000). After washing with TBS-T
(3 times), the membrane was incubated in TBS-T containing 5% BSA and
peroxidase-conjugated secondary antibody (anti-rabbit IgG horseradish peroxidase
(HRP)-linked antibody, Cell Signaling Technology, Cat. No 7074 S, dilution
1:1000); anti-mouse IgG horseradish peroxidase (HRP)-linked antibody, Cell Sig-
naling Technology, Cat. No 7076P2, dilution 1:1000) for 60 min at room tem-
perature. After washing, proteins were visualized with detection reagents
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(Detection Reagent 1 Peroxide Solution and Detection Reagent 2 Luminol
Enhancer Solution) and western blot signals were quantified with ImageJ v.1.47
(wayne Rasband, National Institute of Health, USA). Signal levels of phospho-PKC
and phospho-PKA were normalized to total PKC and PKA, respectively. The same
experiment was repeated with incubation of GH3 cells and the siRNAs targeting
Gαs, Gαq/11, Gα12/13 or the nontargeting siRNA (NTS) (1 µM) (according to the
manufacturer’s instructions) in the siRNA delivery medium. After 24 h, cells were
transiently transfected with empty vector (MOCK) or pcDNA3.1 FLAG-GPR101
(using lipofectamine 3000). Forty-eight hour later, cells were harvested and pro-
teins were detected by western blot.
Growth hormone secretion. For in vitro GH secretion, GH3 cells were seeded on
24-well plates and transfected with MOCK or GPR101 or GHSR or GHRHR
expression vector. After 24 h, the cells were starved for 3 h at 37 °C and GHSR and
GHRHR were stimulated with vehicle or their agonists GHRH (10 nM) and GHS
(10 nM), respectively (for 15 min at 37 °C). After incubation, the medium was
collected at different time points (0, 1, 2, and 6 h) and centrifuged at 12,000 × g for
10 min. The concentrations of GH in the supernatant were determined using the
Growth Hormone Rat ELISA Kit (Merck Millipore, Cat. No EZRMGH-45K)
according to the manufacturer’s instructions. The same experiment was repeated
with incubation of GH3 cells and the siRNAs targeting Gαs, Gαq/11, Gα12/13 or the
nontargeting siRNA (NTS) (according to the manufacturer’s instructions) in the
siRNA delivery medium. After 24 h, cells were transiently transfected with empty
vector (MOCK) or pcDNA3.1.FLAG-GPR101 or pcDNA3.1.FLAG-GHRHR or
pcDNA3.1.GHSR (using lipofectamine 3000). 48 h later, cells were starved for 3 h
at 37 °C and GHSR and GHRHR were stimulated with vehicle or their agonists
GHRH (10 nM) and GHS (10 nM), respectively (for 15 min at 37 °C). After
incubation, the media were collected at different time points (0, 1, 2, and 6 h) and
centrifuged at 12,000 × g for 10 min. The concentrations of GH in the supernatant
were determined by using the GH Rat ELISA Kit according to the manufacturer’s
instructions. In case of using molecules, GH3 cells were seeded in 24-well plates
and transfected with empty vector (MOCK) or pcDNA3.1 FLAG-GPR101. After
24 h, cells were treated with Calphostin C (10 µM) or H89 (10 µM). The day after,
cells were then starved at 37 °C and at the end of incubation, the medium was
removed at different time points (0, 1, 2, and 6 h) and centrifuged at 12,000 × g for
10 min, and the supernatants were used for the hormone assay. Secreted GH in the
medium was measured using the Growth Hormone Rat ELISA Kit.
XTT cell proliferation assay to measure cell growth. GH3 cells were seeded in
96-well flat-bottom microplates. Twenty-four hour later, cells were transfected with
increasing concentrations (0, 25, 50, and 100 ng) of empty vector or GPR101 or
GHRHR or GPR101+GHRHR. Then, the cells were stimulated with various
amounts of vehicle or GHRH (0–300 nM) (final volume of 100 μl per well) at 37 °C
for 24 h. After the incubation period, 50 μl of the XTT (sodium 3′-[1-[(phenyla-
mino)-carbony]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid
hydrate) labeling mixture (mix 5 ml XTT labeling reagent with 0.1 ml electron
coupling reagent) were added to each well, and the microplate was incubated for
4 h at 37 °C and 5% CO2. After this incubation period, the formazan dye formed is
quantified by measuring the optical density of the samples using the WALLAC
VICTOR 2 microplate reader (Perkin Elmer Life Sciences). The wavelength to
measure absorbance of the formazan product is 450 nm. For the use of siRNAs,
GH3 cells were plated in 96-well plates and allowed to adhere overnight. Accell
siRNAs (Gαs, Gαq/11, and Gα12/13) were added to Accell siRNA delivery medium
(supplemented with 2% FBS) for a final concentration of 1 μM. 100 μL of the Accell
siRNA and medium mixture was then added (per well) to the cells after the growth
medium had been aspirated. Cells were incubated for 24 h at 37 °C and 5% CO2,
and then transfected with MOCK, GPR101, GHRHR or GHSR for an additional
24 h. After this incubation time, cells were respectively treated with vehicle or
GHRH (10 nM) or GHS (10 nM) for an additional 24 h, and GH3 viability was
assessed by the XTT method. To study the effects of different molecules, rat GH3
cells were cultured and transfected with MOCK or GPR101. After 48 h, cells were
treated with vehicle (0.1% DMSO), H89 (10 µM), 8-Br-cAMP (10 µM), FSK
(10 µM), or calphostin C (10 µM) overnight at 37 °C. To terminate experiments,
XTT was directly added to the culture media in order to measure cell growth.
Animals. All mice were bred and maintained on a C57BL/6 J genetic background
and were housed in standard cages under specific pathogen-free conditions, fed
standard mouse chow and water ad libitum and kept on a 12 h light/dark cycle. All
experiments were approved by the animal care and use committee of the University
of Liège under the accredited protocol number 1812 and 1776.
Construction of the promGHRHR-FLAG-Gpr101 transgene and generation of
transgenic GhrhrGpr101 mice. A 1948-bp rat GHRHR promoter sequence64 (NCBI,
accession number AF 121969.1) was obtained from rat tail genomic DNA (pur-
ification by the Quick DNA Universal Kit, Zymo Research, Cat. No D4068) and
amplified by Polymerase Chain Reaction (PCR) using the following primers:
Forward primer, 5′-GAGAGGATCCCCATGGCCTCTGCATCAACTTCTG-3′;
Reverse primer, 5′-GAGACTCGAGCTGTAGTCCGCCCCAAAGAG-3′. Then, the
PCR-amplified 1948-bp GHRHR promoter was subcloned into the pcDNA3.1
plasmid by using the BamHI and XhoI restriction sites, and its authenticity was
verified by DNA sequencing. The 1587pb- mouse Gpr101 construct following a
FLAG epitope and preceding a poly-adenylation (poly A) signal sequence was
amplified by PCR from the pcDNA3.1 FLAG-Gpr101 and flanked by XhoI and
XbaI cloning sites with the primers: Forward primer, 5′-GAGACTCGA-
GaccATGGATTATAAAGATGATGATGATAAA-3′; Reverse primer, 5′-
GAGAccTCTAGAccTTAAGGTGAAGTAGCTGAATCATG-3′. Subsequently, the
XhoI-XbaI fragment (containing FLAG-Gpr101-Poly A) was transferred into the
pcDNA3.1 plasmid downstream of the GHRHR promoter sequence. Its authenti-
city was also verified by DNA sequence analysis. The linear 3871bp- transgene
DNA (promGHRHR-FLAG-Gpr101-poly A) was obtained by PCR and purified by
using Wizard® SV Gel and PCR Cleanup System (Promega, Cat. No A9281) and
Minielute® Reaction Cleanup Kit (Qiagen, Cat. No28204). This highly purified
DNA (20 ng µl−1) was microinjected into the pronuclei of fertilized eggs of C57BL/
6 J mice at the GIGA-Transgenesis platform of the university of Liège (Belgium).
Microinjected eggs were transferred into the uteri of female mice and allowed to
develop to term.
Immunofluorescence of pituitary tissues. Pituitaries from 29-week-old
GhrhrGpr101 and WT mice were fixed overnight with 4% paraformaldehyde (PFA)
at 4 °C and paraffin-embedded. Then, tissues were sectioned at 5 μm and mounted
on Superfrost® Microscope Slides (Thermo ScientificTM, Cat. No 12372098). After
deparaffinization and antigen heat retrieval (using citrate buffer at pH 6), sections
were washed with PBS, and permeabilized at room temperature for 10 min with
PBS containing 0.5% Triton X-100. After wash, they were blocked in blocking
buffer (PBS containing 5% FBS and 0.5% Triton X-100) for 60 min, and then
incubated with a primary antibody [polyclonal rabbit anti-GHRHR (LSBio, Cat. No
LS-B6566, dilution 1:100) or rabbit anti-Pit-1 (Novus Biologicals, Cat. No NBP1-
92273, dilution 1:500) or goat anti-GH (R&D systems, Cat. No AF1067-SP, dilu-
tion 1:133) antibody] overnight at 4 °C. Sections were subsequently washed three
times in PBS containing 0.5% Triton X-100, prior to a 2 h room temperature
incubation with the secondary antibody [anti-rabbit IgG (H+ L) F(ab’)2 fragment
Alexa Fluor 647 conjugate (Cell Signaling Technology, Cat. No 4414, dilution
1:1000) or anti-goat Alexa Fluor 488 conjugate (Abcam, Cat. No ab150129, dilution
1:200) antibody]. After, sections were washed three times in PBS containing 0.5%
Triton X-100 and incubated with a monoclonal mouse anti-FLAG antibody
(Sigma–Aldrich, Cat. No F3165, clone M2, dilution 1:1000) for 2 h at room tem-
perature. Sections were again washed three times in PBS containing 0.1% Triton X-
100 and incubated with the secondary antibody [anti-mouse IgG Fab2 Alexa Fluor
488 conjugate (Cell Signaling Technology, Cat. No 4408 S, dilution 1:1000) or anti-
mouse-IgG-Atto 647 N conjugate (Sigma–Aldrich, Cat. No 50185, dilution 1:200)
antibody] for 2 h at room temperature. Sections were then washed three times in
PBS containing 0.5% Triton X-100 and mounted using ProLong Gold Antifade
Mountant containing DAPI (ThermoFisher Scientific, Cat. No P36931). Finally,
stained pituitaries were visualized by confocal microscopy and image acquisition
was performed on a NIKON A1R (Tokyo, Japan) confocal microscope (oil
immersion objective, ×60 magnification).
Determination of plasma hormones. The blood of 6-, 26-, and 52-week-old
GhrhrGpr101 and WT mice were collected from the inferior vena cava in EDTA
capillary blood tubes (Greiner, Cat. No 450475) and the plasma was separated from
cells by centrifugation (2000 × g) for 10 min. Plasma hormone levels were deter-
mined using commercial ELISA immunoassays according to the protocol of the
manufacturers. Mouse GH was detected and quantified by using the Rat/Mouse
Growth Hormone ELISA Kit (Merck Millipore, Cat. No EZRMGH-45K). Mouse
PRL was detected and quantified by using the PRL Mouse ELISA Kit (Thermo-
Fisher Scientific, Cat. No EMPRL). Mouse IGF-1 was detected and quantified by
using a Mouse/Rat IGF-I Quantikine ELISA Kit (Biotechne, Cat. No MG100).
Pituitary superfusion assay. Pituitary glands from 29-week-old GhrhrGpr101 and
WT mice were excised and immediately washed in superfusion chambers (0.5 ml
volume) for 30 min at 37 °C in oxygenated Dulbecco’s Modified Eagle’s Medium
(containing L-glutamine, 4.5 g/L glucose, 25 mM HEPES) supplemented with
BSA (0.1%). Then, they were superfused with the same medium (at a rate of
0.1 ml min−1). After 2 h of equilibration, effluents (500 µl) were collected every
5 min. Mouse GHRH (100 nM) and KCl (0.03 M) were added to the medium for
15 and 20 min, respectively, separated by superfusion with medium alone.
Samples were stored at −80 °C until GH determination by the Rat/Mouse Growth
Hormone ELISA Kit (Merck Millipore, Cat. No EZRMGH-45K). For the quan-
tification of total protein concentration, WT and GhrhrGpr101 pituitary glands
were excised weighted (by an analytical balance) and lysed in RIPA buffer
(Invitrogen, Cat. No 89900) containing protease inhibitors for 30 min at 4 °C.
Protein extracts were then obtained by centrifugation (25,200 × g, 15 min, 4 °C) to
remove tissue debris. The BCA protein assay (Thermo scientific, USA, PierceTM
Protein Assay Kit, Cat. No 23227) was used to measure total protein con-
centrations (in pituitaries) compared to a protein (BSA) standard.
Histology of mouse pituitaries and fat. Mouse pituitaries and epidydimal white
fat were isolated from 27-week-old GhrhrGpr101 and WT mice, washed in PBS and
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fixed in 4% PFA at 4 °C overnight. After that they were embedded into paraffin, cut
with a microtome (5 μm section), mounted on Superfrost® Microscope Slides and
stained with H&E (Merck, Cat. No 1.05174.1000 and 1.09844.1000, respectively).
Photos were taken with a FSX100 microscope equipped with a camera (Olympus,
USA) using ImageJ v.1.47 (wayne Rasband, National Institute of Health, USA).
Adipocyte size (or area) was calculated using Adiposoft v1.15 plug-in software
(Center for Applied Medical Research CIMA, University of Navarra, Spain).
Reticulin staining. Five micrometer paraffin-embedded pituitary sections of 27-
week-old GhrhrGpr101 and WT mice were stained with the Reticulum Stain Kit
(Sigma–Aldrich, Cat. No HT102A-1KT) as recommended by the manufacturer.
Oil Red O staining. Liver tissues were isolated from the 27-week-old GhrhrGpr101
and WT mice, washed in PBS and fixed in 4% PFA at 4 °C overnight. After that,
tissues were immersed in 30% sucrose overnight and they were cut with a cryostat
(7μm thickness), mounted on Superfrost® Plus Microscope Slides (Thermo Sci-
entificTM, Cat. No J1800AMNT), and stained with Oil Red O (ORO)
(Sigma–Aldrich, Cat. No O0625) following the manufacturer’s protocols. Photos
were taken with the FSX100 microscope.
Detection of the Ki-67 cell proliferation marker by immunohistochemistry and
immunofluorescence. After paraffin removal and antigen retrieval (using citrate
buffer at pH 6), pituitary sections from 27-week-old GhrhrGpr101 and WT mice
were incubated in Hydrogen Peroxide (H2O2, 0.3%) for 10 min to block endo-
genous peroxidase activity. After that, sections were stained with rabbit polyclonal
anti-Ki-67 antibody (Merck, Cat. No AB9260) (dilution 1:300) by using the Rabbit
Specific HRP/DAB (ABC) Detection IHC kit (abcam, Cat. No ab64264) according
to the manufacturer’s protocol. Photos were taken with the FSX100 microscope.
The Ki-67 index was quantified by determining the number of Ki-67 positive cells
among the total number of cells. In the immunofluorescence protocol, pituitary
sections were blocked in 5% FBS and incubated with a goat anti-GH polyclonal
antibody overnight at 4 °C. Then, sections were washed and incubated with an anti-
goat AF 488 conjugate antibody (dilution 1:200) for 2 h at room temperature. After
washing, sections were incubated with the rabbit anti-Ki-67 antibody (dilution
1:300) for 2 h at room temperature. Sections were again washed and incubated with
an anti-rabbit AF 647 conjugate antibody (dilution 1:1000) for 2 h at room tem-
perature. Finally, sections were washed in PBS, mounted on slides, air-dried
overnight and visualized by using the NIKON A1R confocal microscope (×60
magnification).
Length and weight of body, organs and bones. Body weight of female and male
GhrhrGpr101 and WT mice was measured once a week (starting at 3 weeks and
ending at 53 weeks) by using a weighing scale. Tail length as well as mouse body
length (from the tip of nose to the anus) were measured with a caliper under
anesthesia (4% isoflurane) from 3 weeks until 69 weeks of age. For the femur, 27-
week-old GhrhrGpr101 J mic/J mice were euthanized and left and right femurs were
removed and dissected free of soft tissue. Femur lengths were measured using a
micrometer caliper. The organ (liver, kidney, heart, lung, testis, and epidydimal fat)
weights were measured with an analytical balance.
MicroCT imaging. The 27-week-old GhrhrGpr101 and WT mice underwent an
in vivo X-ray computed tomography images to assess the mice body composition
in terms of volume. The CT scans were acquired on an eXplore 120 micro-CT
(Gamma Medica, USA/GE Healthcare, UK) with a customized protocol (70 kV,
0.512 mAs, 360 views over 360°, continuous rotation) provided by the manu-
facturer. The software for data collection was Host Console Interface and Micro-
View ABA 2.3.a7. During the imaging session, mice were under general anesthesia
by isoflurane (in a mixture of 30% of O2 in air), placed in prone position in a
dedicated animal holder equipped with an air warming system (Equipment
Minerve, Esternay, France). The mice were continuously monitored (respiratory
rate and temperature). All micro-CT images were reconstructed using the Feld
Kamp’s filtered back projection algorithm with a cutoff at the Nyquist frequency to
obtain a 3D volume with an isotropic voxel size of 100 μm. In order to assess the
CT signal intensity of the adipose tissue, CT scans of different freshly harvested fat
types (epidydimal white fat, subcutaneous white fat, adrenal white fat, and brown
fat) were also acquired.
Assessment of body composition. CT images were used to assess the fat volume
as well as lean volume. For this aim a semi-automated segmentation procedure
was employed using PMOD 3.6 software (PMOD Technologies, Zurich, Swit-
zerland; RRID:SCR_016547). Briefly, an intensity threshold range (−280 to
−160 HU (Hounsfield unit)) for fat was obtained based on the images of the
ex vivo harvested fat types. In vivo CT image of the whole mouse was first
manually segmented to remove the bed and all extra signal (e.g. tubes of
warming system). The resulting image was then sent to the PMOD automated
segmentation to extract the fat part. Based on the mean signal intensity
(threshold for bone: 250 HU), extracted on a spherical region of interest placed
on the bone, binary mask of the bone was extracted using automated
segmentation method implemented in PMOD. A total body mask was also
generated using a range of signal intensities containing fat, bone, and muscle.
Knowing the voxel size and the number of voxels in the obtained masks, the
volume of fat, bone, and total body were calculated. The % of Fat mass was
calculated as follow:
% Fat mass ¼ Fat volume ´ 100=Total body volume
% Bones ¼ Bone volume ´ 100=Total body volume
% Lean mass ¼ Total body volume Bone volumeþ Fat volumeð Þ½  ´ 100=Total body volume
We also used the segmented bone images to measure the length of bones such
as tibia, femur, humerus, and ulna, as well as skull and pelvic dimensions.
Glucose tolerance test. Female and male GhrhrGpr101 and WT mice (11 months)
were used for the glucose tolerance test after a 12h-lasting overnight food-
withdrawal (overnight fasting). Blood glucose levels were measured by collecting
one drop of blood from the tail and using the Accu-Chek® Aviva glucose analyzer
(Roche, Mannheim, Germany, Cat. No 06988563016). For the glucose tolerance
test, mice were administered IP with D-glucose (2 g kg−1 body weight), and the
blood glucose levels were measured at 30, 60, and 90 min after glucose injection.
Upon completion of the experiment, mice were placed in a cage supplied with food
and water.
Activation of PKC in human GH-secreting pituitary adenomas. Human GH-
secreting (GH-omas) pituitary adenomas were obtained by surgery from acrome-
galic patients (with and without AIP mutations), and from patients with X-LAG.
Patients provided written informed consent and the study was performed with the
approval of the Ethical Committee of the Centre Hospitalier Universitaire de Liège.
Pituitary tumors were fixed with 4% PFA at 4 °C overnight and paraffin-embedded.
Tissues were sectioned at 5 μm and mounted on Superfrost glass slides. Paraffin-
embedded sections from mouse pituitaries (29-week-old GhrhrGpr101 J mic/J mice),
human aryl hydrocarbon receptor interacting protein (AIP) mutated GH-omas,
human X-LAG tumors and human GH-omas without an underlying genetic cause
were deparaffinized and antigen retrieval was performed using citrate buffer (pH
6). Sections were washed with PBS, and permeabilized at room temperature for
10 min with PBS containing 0.5% Triton X-100. After wash, sections were blocked
in blocking buffer (PBS containing 5% FBS and 0.5% Triton X-100) for 60 min. For
PKC activation, sections were incubated with an anti-phospho-PKCα (Thr638)
rabbit polyclonal antibody (Life Technologies, Cat. No 44-962 G) diluted (1:500) in
blocking buffer overnight at 4 °C. Sections were subsequently washed three times in
PBS containing 0.5% Triton X-100, prior to the incubation with the secondary
antibody, anti-rabbit IgG Fab2 Alexa Fluor 647 (#4414 S, Cell Signaling Technol-
ogy, Danvers, MA, USA) diluted (1:1000) in blocking buffer for 2 h at room
temperature. Sections were washed three times in PBS containing 0.5% Triton X-
100 and mounted using ProLong Gold Antifade Mountant containing DAPI
(Molecular Probes, ThermoFisher Scientific, Waltham, MA, USA, Cat. No
P36931). Cells were visualized by confocal microscopy and image acquisition was
performed on a confocal microscope NIKON A1R (oil immersion objective ×60,
Tokyo, Japan).
Data analysis. Data were analyzed using GraphPad Prism v.6 (GraphPad Soft-
ware, San Diego, CA, USA), Microsoft Excel (Microsoft Office, Microsoft®, USA,
version 16.16.24 (200713)) and ImageJ v.1.47 (National Institutes of Health, USA)
bundled with Java 1.8.0_172. Statistical analysis was performed with statistical
significance determined as follow: not significant (ns) p > 0.05, *p < 0.05, **p <
0.01, and ***p < 0.001. If the data followed a Gaussian distribution, we compared
them using unpaired t-test. However, if the normal distribution of data or the
homogeneity of their standard deviation was not verified, we compared them using
the nonparametric Mann–Whitney test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All the data and materials are available from the authors upon reasonable request. Source
data are provided with this paper.
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